These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10929)

  • 21. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
    Rees ED; Hamilton RD; Kanner IF; Wasson S; Hearn T
    Atherosclerosis; 1976 Sep; 24(3):537-46. PubMed ID: 788722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precursors of plasma triglyceride fatty acid in humans. Effects of glucose consumption, clofibrate administration, and alcoholic fatty liver.
    Barter PJ; Nestel PJ; Carroll KF
    Metabolism; 1972 Feb; 21(2):117-24. PubMed ID: 5009387
    [No Abstract]   [Full Text] [Related]  

  • 23. Halofenate versus clofibrate in the management of true diabetes insipidus.
    Gattereau A; Davignon J; Verdy M; Lewis W
    Can Med Assoc J; 1974 Jun; 110(11):1275-77. PubMed ID: 4834432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of 2-acetoamidoethyl (p-chloro-phenyl) (m-trifluoromethylphenoxy) acetate (halofenate) on hepatic drug metabolism in retired breeder rats.
    Anthony LE; Jones AL
    Proc Soc Exp Biol Med; 1977 Jan; 154(1):142-5. PubMed ID: 402655
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of S-8527 (1,1-bis4'-(1"-carboxy'1"-methylpropoxy)-phenyl)-cyclohexane), a new hypolipidemic compound, on triglyceride metablolism in rats.
    Suzuki K
    Biochem Pharmacol; 1975 Jun; 24(11-12):1203-7. PubMed ID: 237511
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of 2-acetoamidoethyl (p-chlorophenyl) (m-trifluoromethylphenoxy) acetate (halofenate) on cholesterol oxidation by rat liver mitochondria.
    Kritchevsky D; Tepper SA
    Proc Soc Exp Biol Med; 1972 Apr; 139(4):1284-7. PubMed ID: 5023326
    [No Abstract]   [Full Text] [Related]  

  • 27. The interaction between halofenate and propranolol.
    Huffman DH; Azarnoff DL; Shoeman DW; Dujovne CA
    Clin Pharmacol Ther; 1976 Jun; 19(6):807-12. PubMed ID: 773588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventive effects of dehydroepiandrosterone acetate on the fatty liver induced by orotic acid in male rats.
    Goto H; Yamashita S; Makita T
    Exp Anim; 1998 Oct; 47(4):257-60. PubMed ID: 10067169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of halofenate on serum thyroid hormone determinations in vitro.
    Karch FE; Morgan JP; Kubasik NP; Sine HE
    J Clin Endocrinol Metab; 1976 Jul; 43(1):26-31. PubMed ID: 820706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
    Kuntzen O; Hehl FJ; Walter E; Zimmermann R
    Arzneimittelforschung; 1978; 28(12):2349-52. PubMed ID: 227420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of halofenate on the serum binding of phenytoin.
    Karch FE; Wardell WM; Dambly M; Gringeri A
    Br J Clin Pharmacol; 1977 Oct; 4(5):625-6. PubMed ID: 911611
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of SaH 42-348, an analog of clofibrate, on lipid metabolism in rats.
    Kritchevsky D; Tepper SA
    Arzneimittelforschung; 1973 Jun; 23(6):858-9. PubMed ID: 4740771
    [No Abstract]   [Full Text] [Related]  

  • 33. Halofenate. Its selection and trial as a primary uricosuric agent.
    Bluestone R; Campion D; Klinenberg JR
    Arthritis Rheum; 1975; 18(6 Suppl):859-62. PubMed ID: 1106434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of hypolipidemic drugs in the prevention of an orotic acid fatty liver.
    Elwood JC; Richert DA; Westerfeld WW
    Biochem Pharmacol; 1972 Apr; 21(8):1127-34. PubMed ID: 5034198
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
    Schapel GJ; Edwards KD
    J Pharmacol Exp Ther; 1975 Jul; 194(1):274-84. PubMed ID: 1171221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anomalous results of studies on drug interaction in man. II. Halofenate (mk-185) and antipyrine, bishydroxycoumarin, and warfarin.
    Vesell ES; Passananti GT
    Pharmacology; 1975; 13(2):112-27. PubMed ID: 49900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of orotic acid-induced fatty liver in rats by clofibrate.
    Novikoff PM; Edelstein D
    Lab Invest; 1977 Feb; 36(2):215-31. PubMed ID: 839735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
    Keller C; Wolfram G; Zöllner N
    Arzneimittelforschung; 1976; 26(12):2221-4. PubMed ID: 798591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs affecting the synthesis of glycerides and phospholipids in rat liver. The effects of clofibrate, halofenate, fenfluramine, amphetamine, cinchocaine, chlorpromazine, demethylimipramine, mepyramine and some of their derivatives.
    Brindley DN; Bowley M
    Biochem J; 1975 Jun; 148(3):461-9. PubMed ID: 1200988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy?
    Eaton RP; Oase R; Schade DS
    Metabolism; 1976 Mar; 25(3):245-9. PubMed ID: 1250161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.